Literature DB >> 19424739

Etiopathogenesis of hepatic osteodystrophy in Wistar rats with cholestatic liver disease.

F A Pereira1, Inalda Facincani, Vanda Jorgetti, Leandra N Z Ramalho, José B Volpon, Luciene M Dos Reis, Francisco J A de Paula.   

Abstract

The pathophysiology of hepatic osteodystrophy (HO) remains poorly understood. Our aim was to evaluate bone histomorphometry, biomechanical properties, and the role of the growth hormone (GH)/insulin-like growth factor-I (IGF-I) system in the onset of this disorder. Forty-six male Wistar rats were divided into two groups: sham-operated (SO, n = 23) and bile duct-ligated (BDL, n = 23). Rats were killed on day 30 postoperatively. Immunohistochemical expression of IGF-I and GH receptor was determined in liver tissue and in the proximal growth plate cartilage of the left tibia. Histomorphometric analysis was performed in the right tibia, and the right femur was used for biomechanical analysis. The maximal force at fracture and the stiffness of the mid-shaft femur were, respectively, 53% and 24% lower in BDL compared to SO. Histomorphometric measurements showed low cancellous bone volume and decreased cancellous bone connectivity in BDL, compatible with osteoporosis. This group also showed increased mineralization lag time, indicating disturbance in bone mineralization. Serum levels of IGF-I were lower in BDL (basal 1,816 +/- 336 vs. 30 days 1,062 +/- 191 ng/ml, P < 0.0001). BDL also showed higher IGF-I expression in the liver tissue but lower IGF-I and GH receptor expression in growth plate cartilage than SO. Osteoporosis is the most important feature of HO; BDL rats show striking signs of reduced bone volume and decreased bone strength, as early as after 1 month of cholestasis. The endocrine and autocrine-paracrine IGF-I systems are deeply affected by cholestasis. Further studies will be necessary to establish their role in the pathogenesis of HO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424739     DOI: 10.1007/s00223-009-9249-3

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

Review 1.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

2.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

3.  Ex vivo vibro-acoustography characterization of osteoporosis in an experimental mice model.

Authors:  Paulo Moraes Agnollitto; Guilherme de Araújo Braz; Adriano Levi Spirlandeli; Francisco José Albuquerque de Paula; Antonio Adilton Oliveira Carneiro; Marcello Henrique Nogueira-Barbosa
Journal:  Quant Imaging Med Surg       Date:  2021-02

4.  Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.

Authors:  Adriano L Spirlandeli; Ingrid Dick-de-Paula; Ariane Zamarioli; Vanda Jorgetti; Leandra N Z Ramalho; Marcello H Nogueira-Barbosa; Jose B Volpon; Alceu A Jordão; Fernando Q Cunha; Sandra Y Fukada; Francisco J A de Paula
Journal:  Clinics (Sao Paulo)       Date:  2017-04       Impact factor: 2.365

5.  Acacia sieberiana (Fabaceae) attenuates paracetamol and Bile Duct Ligation-Induced hepatotoxicity via modulation of biochemical and oxidative stress biomarkers.

Authors:  Miriam Watafua; Jane I Ejiofor; Aminu Musa; Mubarak Hussaini Ahmad
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

6.  Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody.

Authors:  Yusuke Kawazoe; Mutsumi Miyauchi; Atsuhiro Nagasaki; Hisako Furusho; Syunryo Yanagisawa; Chea Chanbora; Toshihiro Inubushi; Hideyuki Hyogo; Takashi Nakamoto; Keiko Suzuki; Sawako Moriwaki; Susumu Tazuma; Shumpei Niida; Takashi Takata
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

7.  Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats.

Authors:  F A Pereira; R Mattar; I Facincani; H L A Defino; L N Z Ramalho; V Jorgetti; J B Volpon; F J A de Paula
Journal:  Braz J Med Biol Res       Date:  2012-09-11       Impact factor: 2.590

8.  Portulaca oleracea methanolic extract attenuate bile duct ligation-induced acute liver injury through hepatoprotective and anti-inflammatory effects.

Authors:  Zahra Moslemi; Mina Bahrami; Ebrahim Hosseini; Mahboubeh Mansourian; Zahra Daneshyar; Mahdieh Eftekhari; Nasrin Shakerinasab; Arash Asfaram; Esmaeel Panahi Kokhdan; Zahra Barmoudeh; Amir Hossein Doustimotlagh
Journal:  Heliyon       Date:  2021-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.